John M. Robertson

Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials

A. Dal Pra, Pirus Ghadjar, Hyunnam Monica Ryu, J.A. Proudfoot et autres

BACKGROUND: The SAKK 09/10 trial randomized biochemically recurrent prostate cancer patients to salvage radiation 64 Gy versus 70 Gy, and the NRG/RTOG 0126 randomized intermediate-risk prostate cancer patients to definitive radiation 70.2 Gy versus 79.2 Gy. We investigated a previously developed Post-Operative …

us, de, ch, ca (code pays fourni par la source)

Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial

Daniel Eidelberg Spratt, Vinnie Y.T. Liu, Jeff M. Michalski, Elai Davicioni et autres

us, ca (code pays fourni par la source)

Addenda

John M. Robertson, Peter Cain

Since these pages were written there has appeared a second edition of Captain Mahan’s Life of Nelson, in which the case against the hero is more fully dealt with by his biographer, the Italian evidence being now taken up. The revised vindication …

THE PROFICIENCE AND ADVANCEMENT OF LEARNING, DIVINE AND HUMAN

John M. Robertson

FILUM LABYRINTHI, SIVE FORMULA INQUISITIONIS (Fragment)

John M. Robertson

Clinical Use of Spirituality in Assessing and Treating Authoritarian Men

John M. Robertson

A Toothbrush and the Boy in the Man I Became

John M. Robertson

An "Ideal" Masculinity: A Buddhist Approach

John M. Robertson

Candidates for Treasurer.

James L Campbell, John M. Robertson

A Phase I trial of hepatic arterial bromodeoxyuridine and conformal radiation therapy for patients with primary hepatobiliary cancers or colorectal liver metastases

John M. Robertson, Cornelius J. McGinn, Suzette Walker, M. Victoria Marx et autres

us (code pays fourni par la source)

Potential benefits of eliminating planning target volume expansions for patient breathing in the treatment of liver tumors

Randall K. Ten Haken, James M. Balter, Lon H. Marsh, John M. Robertson et autres

us (code pays fourni par la source)

A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma

Mace L. Rothenberg, James L. Abbruzzese, Malcolm A.S. Moore, Russell K. Portenoy et autres

BACKGROUND Using classical endpoints, such as response rate and survival, as the sole measures of benefit, little progress has been made in the treatment of advanced pancreatic carcinoma in the past 30 years. We challenge the assumption that response rate and survival …

us, ca (code pays fourni par la source)